Gene therapy player turned kidney specialist Vera drops a dud in leadup to Nasdaq, pricing well below range

Vera Therapeutics took a big risk at the start of the year, pivoting away from its gene editing mission statement to chase a lead kidney drug instead — and they doubled down with an IPO just months later. But investors don’t seem impressed with Vera’s promise, and now the biotech...

Click to view original post